ArticleBritish journal of cancer2023
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.
Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.International journal of molecular sciences · 2026Observational
- Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer.Cancer research and treatment · 2026Article
- Neoadjuvant pyrotinib for HER2 (IHC 2+/FISH+)/HR+ breast cancer with early non-response: a case report and literature review.Frontiers in medicine · 2026Article
- The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Integration of tumor microenvironment and metabolic signatures reveals TMPI-defined prognostic and immunotherapy-relevant phenotypes in breast cancer.Frontiers in pharmacology · 2026Article
- Impact of HER2 immunohistochemistry score on pathological complete response and survival in HER2-positive breast cancer treated with neoadjuvant therapy: differential outcomes by hormone receptor status.Frontiers in oncology · 2026Article
- HER2 expression in breast cancer: evidence gaps and challenges.NPJ precision oncology · 2025Review
- Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.Breast cancer (Tokyo, Japan) · 2025Review
- Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement.The Indian journal of medical research · 2025Review
- Characterisation of HER2-Driven Morphometric Signature in Breast Cancer and Prediction of Risk of Recurrence.Cancer medicine · 2025Article
- Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2-Overexpressing Breast Cancers.Annals of surgical oncology · 2025Article
- Current research status on HER2 protein expression levels and the efficacy of targeted therapy in breast cancer.Frontiers in oncology · 2025Review
- Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer.Journal of Cancer · 2025Article
- Prospective Validation of a One-Step RT-qPCR-based Test for Quantifying HER2 Gene Expression in Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Predictors of pathological complete response to neoadjuvant treatment in invasive breast cancer with different human epidermal growth factor receptor 2 (HER2) subcategories.Quantitative imaging in medicine and surgery · 2024Article
- GP100 expression is variable in intensity in melanoma.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Case report: Near-complete response to neratinib-based treatment in HR-positiveFrontiers in oncology · 2024Article
- Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.Pathologica · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing data indicate that HER2-positive (HER2 + ) breast cancer (BC) subtypes exhibit differential responses to targeted anti-HER2 therapy. This study aims to investigate these differences and the potential underlying molecular mechanisms.
methodsA large cohort of BC patients (n = 7390) was utilised. The clinicopathological characteristics and differential gene expression (DGE) of HER2+ immunohistochemical (IHC) subtypes, specifically HER2 IHC 3+ and IHC 2 + /Amplified, were assessed and correlated with pathological complete response (pCR) and survival in the neoadjuvant and adjuvant settings, respectively. The role of oestrogen receptor (ER) status was also investigated.
resultsCompared to HER2 IHC 3+ tumours, BC patients with IHC 2 + /Amplified showed a significantly lower pCR rate (22% versus 57%, P < 0.001), shorter survival regardless of HER2 gene copy number, were less classified as HER2 enriched, and enriched for trastuzumab resistance and ER signalling pathway genes. ER positivity significantly decreased response to anti-HER2 therapy in IHC 2 + /Amplified, but not in IHC 3 + BC patients.
conclusionIn HER2 + BC, overexpression of HER2 protein is the driver of the oncogenic pathway, and it is the main predictor of response to anti-HER2 therapy. ER signalling pathways are more dominant in BC with equivocal HER2 expression. personalised anti-HER2 therapy based on IHC classes should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.